| Serial Number | 87739259 |
| Word Mark | TINNESTA |
| Filing Date | Sunday, December 31, 2017 |
| Status | 606 - ABANDONED - NO STATEMENT OF USE FILED |
| Status Date | Monday, July 26, 2021 |
| Registration Number | 0000000 |
| Registration Date | NOT AVAILABLE |
| Mark Drawing | 4000 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form |
| Published for Opposition Date | Tuesday, April 24, 2018 |
| Goods and Services | Drug delivery agents consisting of compounds that facilitate delivery of a wide range of pharmaceuticals; Drug delivery agents in the form of capsules that provide controlled release of the active ingredients for a wide variety of pharmaceuticals; Drug delivery agents in the form of powders that provide controlled release of the active ingredients for a wide variety of pharmaceuticals; Drug delivery agents in the form of tablets that provide controlled release of the active ingredients for a wide variety of pharmaceuticals; Drug delivery agents in the form of orodispersable tablets and/or sublingual tablets that facilitate the delivery of pharmaceutical preparations; Nutraceuticals for use as a dietary supplement; Pharmaceutical agents affecting digestive organs; Pharmaceutical agents affecting metabolism; Pharmaceutical agents affecting peripheral nervous system; Pharmaceutical agents affecting sensory organs; Pharmaceutical for the treatment of erectile dysfunction; Pharmaceutical preparations acting on the central nervous system; Pharmaceutical preparations and substances for the treatment of damaged skin and tissue; Pharmaceutical preparations and substances for the treatment of gastro-intestinal diseases; Pharmaceutical preparations and substances for the treatment of infectious diseases, blood disorders, pain, inflammation, sepsis, alopecia, obesity and cognitive disorders; Pharmaceutical preparations and substances for the treatment of psychiatric diseases and disorders; Pharmaceutical preparations and substances for the treatment of viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, sexual dysfunction, oncological, hepatological, ophthalmic, respiratory, neurological, gastrointestinal, hormonal, dermatological, psychiatric and immune system related diseases and disorders; Pharmaceutical preparations for inhalation for the treatment of pulmonary hypertension; Pharmaceutical preparations for peripheral nervous system; Pharmaceutical preparations for skin care; Pharmaceutical preparations for the treatment of the cardiovascular system, the circulatory system, the digestive system, the excretory system, the endocrine system, the integumentary system, the exocrine system, the lymphatic system, the immune system, the muscular system, the nervous system, the renal system, the urinary system, the reproductive system, and/or the skeletal system; Pharmaceutical preparations for the treatment of heart rhythm disorders; Pharmaceutical preparations for the treatment of hormonal disorders and the prevention of osteoporosis; Pharmaceutical preparations for the treatment of hypercholesteremia; Pharmaceutical preparations for the treatment of hyperlipidemia; Pharmaceutical preparations for the treatment of immune system related diseases and disorders; Pharmaceutical preparations for the treatment of infectious diseases; Pharmaceutical preparations for the treatment of kidney diseases; Pharmaceutical preparations for the treatment of musculo-skeletal disorders; Pharmaceutical preparations for treating allergic rhinitis and asthma; Pharmaceutical preparations for treating allergies; Pharmaceutical preparations for treating chemical imbalances; Pharmaceutical preparations for treating diabetes; Pharmaceutical preparations for treating hypertension; Pharmaceutical preparations for treating skin disorders; Pharmaceutical preparations for use in dermatology; Pharmaceutical preparations for use in urology; Pharmaceutical preparations, namely, a drug delivery system comprising polymer-based oral tablets for the continuous release of a wide variety of therapeutic agents; Pharmaceutical preparations, namely, an analgesic for human consumption taken orally; Pharmaceutical products for the prevention and treatment of cancer; Pharmaceutical products for the treatment of joint disease; Pharmaceutical products for the treatment of viral and infectious diseases, for the treatment of cancer; Pharmaceutical products for treating respiratory diseases; Pharmaceutical products for treating respiratory diseases and asthma; Pharmaceutical solutions used in dialysis; Pharmaceuticals for the treatment of erectile dysfunction; Pharmaceuticals, namely, lipid lowering agents; Pharmaceuticals, namely, psychotropics; Cardiovascular pharmaceuticals; Chemical preparations for pharmaceutical or medical purposes, namely, for treatment of the endocannabinoid; Human vaccine preparations; Oral vaccine preparations |
| International Class | 005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides. |
| US Class Codes | 006, 018, 044, 046, 051, 052 |
| Class Status Code | 6 - Active |
| Class Status Date | Tuesday, January 16, 2018 |
| Primary Code | 005 |
| First Use Anywhere Date | NOT AVAILABLE |
| First Use In Commerce Date | NOT AVAILABLE |
| Party Name | Sentar Pharmaceuticals |
| Party Type | 20 - Owner at Publication |
| Legal Entity Type | 03 - Corporation |
| Address | Irvine, CA 92614 |
| Party Name | Sentar Pharmaceuticals |
| Party Type | 10 - Original Applicant |
| Legal Entity Type | 03 - Corporation |
| Address | Irvine, CA 92614 |
| Event Date | Event Description |
| Monday, July 26, 2021 | ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED |
| Monday, July 26, 2021 | ABANDONMENT - NO USE STATEMENT FILED |
| Tuesday, January 5, 2021 | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED |
| Monday, January 4, 2021 | EXTENSION 5 GRANTED |
| Tuesday, December 8, 2020 | EXTENSION 5 FILED |
| Monday, December 21, 2020 | CASE ASSIGNED TO INTENT TO USE PARALEGAL |
| Tuesday, December 8, 2020 | TEAS EXTENSION RECEIVED |
| Wednesday, June 10, 2020 | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED |
| Monday, June 8, 2020 | EXTENSION 4 GRANTED |
| Monday, June 8, 2020 | EXTENSION 4 FILED |
| Monday, June 8, 2020 | TEAS EXTENSION RECEIVED |
| Thursday, October 17, 2019 | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED |
| Tuesday, October 15, 2019 | EXTENSION 3 GRANTED |
| Tuesday, October 15, 2019 | EXTENSION 3 FILED |
| Tuesday, October 15, 2019 | TEAS EXTENSION RECEIVED |
| Wednesday, May 22, 2019 | TEAS CHANGE OF CORRESPONDENCE RECEIVED |
| Friday, May 24, 2019 | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED |
| Wednesday, May 22, 2019 | EXTENSION 2 GRANTED |
| Wednesday, May 22, 2019 | EXTENSION 2 FILED |
| Wednesday, May 22, 2019 | TEAS EXTENSION RECEIVED |
| Thursday, January 17, 2019 | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED |
| Thursday, January 17, 2019 | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED |
| Friday, December 21, 2018 | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED |
| Wednesday, December 19, 2018 | EXTENSION 1 GRANTED |
| Wednesday, December 19, 2018 | EXTENSION 1 FILED |
| Wednesday, December 19, 2018 | TEAS EXTENSION RECEIVED |
| Tuesday, June 19, 2018 | NOA E-MAILED - SOU REQUIRED FROM APPLICANT |
| Tuesday, April 24, 2018 | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED |
| Tuesday, April 24, 2018 | PUBLISHED FOR OPPOSITION |
| Wednesday, April 4, 2018 | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED |
| Thursday, March 22, 2018 | APPROVED FOR PUB - PRINCIPAL REGISTER |
| Thursday, March 22, 2018 | ASSIGNED TO EXAMINER |
| Tuesday, January 16, 2018 | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED IN TRAM |
| Wednesday, January 3, 2018 | NEW APPLICATION ENTERED IN TRAM |